Adaptimmune Therapeutics (ADAP)

P/S ratio as of November 2026 (TTM): 0.2236

According to Adaptimmune Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -0.2051. At the end of 2023 the company had a P/S ratio of 2.99.

P/S ratio history for Adaptimmune Therapeutics from 2016 to 2023

PS ratio at the end of each year

Year	P/S ratio	Change
2023	2.99	-66.09%
2022	8.81	-90.75%
2021	95.3	-54.81%
2020	211	87.41%
2019	112	1013.07%
2018	10.1	-38.91%
2017	16.5	-18.08%
2016	20.2

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
uniQure QURE	85.6	38,190.50%	🇳🇱 Netherlands
Novavax NVAX	4.34	1,842.35%	🇺🇸 USA
Exelixis EXEL	7.01	3,035.85%	🇺🇸 USA
Enzo Biochem ENZB	1.33	495.63%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Adaptimmune Therapeutics (ADAP)

P/S ratio as of November 2026 (TTM): 0.2236